| P2093 | author name string | A Wesley Burks | |
| | Michele Henson | |
| P2860 | cites work | Future therapies for food allergies | Q24630319 |
| | Effect of anti-IgE therapy in patients with peanut allergy | Q28183354 |
| | Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract1 | Q28243179 |
| | Intestinal barrier function: molecular regulation and disease pathogenesis | Q28250081 |
| | Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel | Q28300001 |
| | A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy | Q28307175 |
| | Oral desensitization for food hypersensitivity | Q34181235 |
| | A controlled trial of immunotherapy in insect hypersensitivity | Q34317781 |
| | The role of protein digestibility and antacids on food allergy outcomes | Q34394239 |
| | Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. | Q34414866 |
| | Differential growth patterns among healthy infants fed protein hydrolysate or cow-milk formulas | Q34439753 |
| | Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. | Q34480913 |
| | Safety, tolerability, and immunologic effects of a food allergy herbal formula in food allergic individuals: a randomized, double-blinded, placebo-controlled, dose escalation, phase 1 study | Q34519061 |
| | The natural history of food allergy. | Q34534115 |
| | Oral tolerance and its relation to food hypersensitivities | Q34553986 |
| | Successful oral tolerance induction in severe peanut allergy | Q34604676 |
| | US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up | Q34619542 |
| | Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization | Q34640733 |
| | Food allergy herbal formula 2 protection against peanut anaphylactic reaction is via inhibition of mast cells and basophils | Q34690654 |
| | A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response | Q34698506 |
| | Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. | Q34837055 |
| | NIAID-sponsored 2010 guidelines for managing food allergy: applications in the pediatric population | Q35530004 |
| | Clinical safety of Food Allergy Herbal Formula-2 (FAHF-2) and inhibitory effect on basophils from patients with food allergy: Extended phase I study | Q35589689 |
| | Mechanisms of immune tolerance relevant to food allergy | Q35599989 |
| | Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy | Q36093954 |
| | Time trends in allergic disorders in the UK. | Q36203245 |
| | The safety and efficacy of sublingual and oral immunotherapy for milk allergy. | Q36220764 |
| | The induction of cell-mediated immunity and tolerance with protein antigens coupled to syngeneic lymphoid cells | Q36341313 |
| | The natural history of peanut and tree nut allergy | Q36797393 |
| | Peanut allergy: emerging concepts and approaches for an apparent epidemic | Q36906296 |
| | ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms | Q36936238 |
| | Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine | Q37067215 |
| | Oral tolerance, food allergy, and immunotherapy: implications for future treatment | Q37138202 |
| | A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy | Q37150568 |
| | The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. | Q37247220 |
| | Clinical efficacy and immune regulation with peanut oral immunotherapy | Q37301616 |
| | Safety of a peanut oral immunotherapy protocol in children with peanut allergy | Q37316978 |
| | Efficacy and mechanisms of action of traditional Chinese medicines for treating asthma and allergy | Q37356837 |
| | Omalizumab in the treatment of severe asthma: efficacy and current problems | Q37362658 |
| | Food allergy among children in the United States | Q37633787 |
| | Pediatric food allergy and mucosal tolerance. | Q37761046 |
| | Specific oral tolerance induction in food allergic children: is oral desensitisation more effective than allergen avoidance?: a meta-analysis of published RCTs. | Q37762634 |
| | Quality of life in food allergy | Q37861505 |
| | Long-term clinical and immunological effects of allergen immunotherapy | Q37944067 |
| | Therapeutics in food allergy: the current state of the art. | Q37958752 |
| | Oral immunotherapy and anti-IgE antibody-adjunctive treatment for food allergy | Q37975653 |
| | Update on risk factors for food allergy | Q37998676 |
| | Antigen-fixed leukocytes tolerize Th2 responses in mouse models of allergy. | Q38939073 |
| | Treatment of peanut allergy with rush immunotherapy | Q41111237 |
| | Peanut oral immunotherapy is not ready for clinical use | Q42732650 |
| | Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy | Q43225422 |
| | Bullying among pediatric patients with food allergy | Q43451696 |
| | An enteric helminth infection protects against an allergic response to dietary antigen. | Q44129528 |
| | Severe anaphylaxis to kiwi fruit: Immunologic changes related to successful sublingual allergen immunotherapy | Q44265145 |
| | Oral desensitizing treatment in food allergy: clinical and immunological results | Q44299630 |
| | Engineered recombinant peanut protein and heat-killed Listeria monocytogenes coadministration protects against peanut-induced anaphylaxis in a murine model | Q44355416 |
| | Schistosoma mansoni infection is associated with a reduced course of asthma | Q44438840 |
| | Persistent protective effect of heat-killed Escherichia coli producing "engineered," recombinant peanut proteins in a murine model of peanut allergy | Q44504353 |
| | The Chinese herbal medicine formula FAHF-2 completely blocks anaphylactic reactions in a murine model of peanut allergy | Q45215097 |
| | Food Allergy Herbal Formula-2 silences peanut-induced anaphylaxis for a prolonged posttreatment period via IFN-gamma-producing CD8+ T cells | Q46128144 |
| | Anti-acids lead to immunological and morphological changes in the intestine of BALB/c mice similar to human food allergy | Q46559183 |
| | Food allergy among U.S. children: trends in prevalence and hospitalizations | Q46779861 |
| | Clinical evaluation of the Chinese herbal medicine formula STA-1 in the treatment of allergic asthma | Q47211405 |
| | Health-related quality of life of food allergic patients measured with generic and disease-specific questionnaires | Q48894860 |
| | Egg oral immunotherapy in nonanaphylactic children with egg allergy. | Q50702311 |
| | Food allergies in children affect nutrient intake and growth. | Q50710913 |
| | Oral peanut immunotherapy in children with peanut anaphylaxis. | Q52903267 |
| | Induction of tolerance after establishment of peanut allergy by the food allergy herbal formula-2 is associated with up-regulation of interferon-gamma. | Q53551457 |
| | Further fatalities caused by anaphylactic reactions to food, 2001-2006. | Q55043255 |
| | Epicutaneous immunotherapy using a new epicutaneous delivery system in mice sensitized to peanuts. | Q55053541 |
| | Specific oral tolerance induction in children with very severe cow's milk–induced reactions | Q57243160 |
| | Household peanut consumption as a risk factor for the development of peanut allergy | Q57414792 |
| | The prevalence of food allergy: A meta-analysis | Q61530424 |
| | Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction | Q66829364 |
| | Oral specific hyposensitization in the management of patients allergic to food | Q70695882 |
| | The effect of Chinese herbal medicine, xiao-qing-long tang (XQLT), on allergen-induced bronchial inflammation in mite-sensitized mice | Q73297903 |
| | Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis | Q77633152 |
| | Oral rush desensitization to milk | Q78257016 |
| | Ding Chuan Tang, a Chinese herb decoction, could improve airway hyper-responsiveness in stabilized asthmatic children: a randomized, double-blind clinical trial | Q79920465 |
| | A protocol for oral desensitization in children with IgE-mediated cow's milk allergy | Q80413023 |
| | Efficacy and safety of modified Mai-Men-Dong-Tang for treatment of allergic asthma | Q81366877 |
| | Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract | Q81454014 |
| | Food allergy | Q82368716 |
| | Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract | Q83272498 |
| | Allergic and anaphylactic response to sesame seeds in mice: identification of Ses i 3 and basic subunit of 11s globulins as allergens | Q83338630 |
| | SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial | Q83346456 |
| | Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity | Q84183803 |
| P433 | issue | 5 | |
| P921 | main subject | food allergy | Q769815 |
| P304 | page(s) | 703-714 | |
| P577 | publication date | 2012-06-27 | |
| P1433 | published in | Seminars in Immunopathology | Q15724576 |
| P1476 | title | The future of food allergy therapeutics | |
| P478 | volume | 34 | |